Results 81 to 90 of about 3,014 (182)

A Unique WHSC1L1‐FGFR1 Fusion in Follicular Dendritic Cell Sarcoma

Pathology International, Volume 76, Issue 8, August 2026.
Pedro Farrajota Neves da Silva, Felix Haglund de Flon, Clas Mercke, George Z. Rassidakis   +3 more
wiley   +1 more source

Bilateral Subretinal Fluid Accumulation during Erdafitinib Therapy

TNOA Journal of Ophthalmic Science and Research
Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of ...
Rajneesh Singh, Nipun Bagrecha, Suresh K. Pandey, Deepesh Chabblani   +3 more
doaj   +1 more source

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors

Therapeutic Advances in Medical Oncology, 2019
Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC).
Chiara Casadei, Nazli Dizman, Giuseppe Schepisi, Maria Concetta Cursano, Umberto Basso, Daniele Santini, Sumanta K. Pal, Ugo De Giorgi   +7 more
doaj   +1 more source

Figure S1A from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

, 2019
Supplementary Figure S1. Mean concentration-time erdafitinib profiles after a single dose (cycle 1 day 1 [C1D1]) and at steady-state (cycle 2 day 1 [C2D1]) after daily dosing (Panel A) or intermittent dosing (Panel B).
Alain Mita (6295982), Alexander Spira (11395472), Ramaswamy Govindan (60360), Martha Gonzalez (3638434), Mark Awad (6525626), Trilok Parekh (15018212), Italo Poggesi (2396347), Jeffrey Infante (3816376), Josep Tabernero (237681), Bob Zhong (15018209), Rastislav Bahleda (13011628), Ademi Santiago-Walker (15001046), Victor Moreno (748751), Hong Xie (133048), Emiliano Calvo (6271580), Andres Cervantes (8456292), Cinta Hierro (15018206), Antoine Italiano (725114), Nancy Chan (6727526)   +18 more
core   +1 more source

Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma [PDF]

Aberrations of the fibroblast growth factor receptor (FGFR) family members are frequently observed in metastatic urothelial cancer (mUC), and blocking the FGF/FGFR signaling axis is used as a targeted therapeutic strategy for treating patients ...
Wörsdörfer, Karin, Hahn, Oliver, Geyer, Matthias, Zanotto, Ilaria, Wachten, Dagmar, Hosni, Sana, Corvino, Dillon, Winkler, Anja, Hölzel, Michael, Klümper, Niklas, Saponaro, Miriam, Kilian, Viola, De Martin, Sara, Alajati, Abdullah, Bertlich, Marina, Gabbia, Daniela, Schmidt, Doris, Bald, Tobias, Sieckmann, Katharina, Toma, Marieta, Eckstein, Markus, Ritter, Manuel   +21 more
core   +2 more sources

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Acta Pharmaceutica
The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment.
Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar   +10 more
doaj   +1 more source

Figure S1B from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

, 2019
Supplementary Figure S1. Mean concentration-time erdafitinib profiles after a single dose (cycle 1 day 1 [C1D1]) and at steady-state (cycle 2 day 1 [C2D1]) after daily dosing (Panel A) or intermittent dosing (Panel B).
Alain Mita (6295982), Alexander Spira (11395472), Ramaswamy Govindan (60360), Martha Gonzalez (3638434), Mark Awad (6525626), Trilok Parekh (15018212), Italo Poggesi (2396347), Jeffrey Infante (3816376), Josep Tabernero (237681), Bob Zhong (15018209), Rastislav Bahleda (13011628), Ademi Santiago-Walker (15001046), Victor Moreno (748751), Hong Xie (133048), Emiliano Calvo (6271580), Andres Cervantes (8456292), Cinta Hierro (15018206), Antoine Italiano (725114), Nancy Chan (6727526)   +18 more
core   +1 more source

CTNI-61. A PHASE 2 STUDY OF ERDAFITINIB IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH-WILD TYPE GLIOMA WITH FGFR-TACC GENE FUSIONS: SAFETY RUN-IN COHORT RESULTS

FGFR-TACC gene fusions (F-T) are the most prevalent fusions in adult glioma, present in 3-6% of IDH-wild-type glioma. F-T emerge as truncal alterations during gliomagenesis, are independent predictors of favorable outcome in gliomas, and are retained in ...
Hill, Colin, Tejera, Dalissa, de la Fuente, Macarena, Kushnirsky, Marina, Iavarone, Antonio, McFaline-Figueroa, J Ricardo, Han, Sunwoo, Bhatia, Ankush, Butt, M Omar, Pelosof, Lorraine, Kaley, Thomas, Vuong, Kimberly   +11 more
core   +2 more sources

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors

, 2019
Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age >= 18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective ...
Cervantes, Andrés, Bahleda, Rastislav, Italiano, Antoine, Hierro, Cinta, Awad, Mark, Tabernero, Josep, Chan, Nancy, Mita, Alain, Moreno, Victor   +8 more
core   +1 more source